EP1171572A2 - Systemes modulaires de support cellulaire pour la croissance cellulaire en trois dimensions - Google Patents
Systemes modulaires de support cellulaire pour la croissance cellulaire en trois dimensionsInfo
- Publication number
- EP1171572A2 EP1171572A2 EP00912550A EP00912550A EP1171572A2 EP 1171572 A2 EP1171572 A2 EP 1171572A2 EP 00912550 A EP00912550 A EP 00912550A EP 00912550 A EP00912550 A EP 00912550A EP 1171572 A2 EP1171572 A2 EP 1171572A2
- Authority
- EP
- European Patent Office
- Prior art keywords
- cell
- segments
- cells
- cell support
- support system
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 230000010261 cell growth Effects 0.000 title description 12
- 210000004027 cell Anatomy 0.000 claims abstract description 143
- 239000011148 porous material Substances 0.000 claims abstract description 29
- 239000012528 membrane Substances 0.000 claims abstract description 13
- 210000000130 stem cell Anatomy 0.000 claims abstract description 4
- 125000006850 spacer group Chemical group 0.000 claims description 11
- 239000007788 liquid Substances 0.000 claims description 3
- 210000001519 tissue Anatomy 0.000 description 25
- 239000010410 layer Substances 0.000 description 24
- 238000000034 method Methods 0.000 description 19
- 235000015097 nutrients Nutrition 0.000 description 19
- 239000000969 carrier Substances 0.000 description 12
- 238000004113 cell culture Methods 0.000 description 12
- 230000004069 differentiation Effects 0.000 description 10
- 230000008901 benefit Effects 0.000 description 9
- 230000008569 process Effects 0.000 description 9
- 238000009826 distribution Methods 0.000 description 8
- 238000004519 manufacturing process Methods 0.000 description 8
- 239000002609 medium Substances 0.000 description 8
- 210000000056 organ Anatomy 0.000 description 8
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 7
- 230000012010 growth Effects 0.000 description 7
- 239000001301 oxygen Substances 0.000 description 7
- 229910052760 oxygen Inorganic materials 0.000 description 7
- 238000000338 in vitro Methods 0.000 description 6
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 5
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 5
- 210000002744 extracellular matrix Anatomy 0.000 description 5
- 238000001727 in vivo Methods 0.000 description 5
- 239000000463 material Substances 0.000 description 5
- 230000035755 proliferation Effects 0.000 description 5
- 238000005538 encapsulation Methods 0.000 description 4
- 238000005516 engineering process Methods 0.000 description 4
- 239000000835 fiber Substances 0.000 description 4
- 210000003292 kidney cell Anatomy 0.000 description 4
- 210000004185 liver Anatomy 0.000 description 4
- 108090000623 proteins and genes Proteins 0.000 description 4
- 102000004169 proteins and genes Human genes 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 239000000725 suspension Substances 0.000 description 4
- 241000264877 Hippospongia communis Species 0.000 description 3
- 238000010276 construction Methods 0.000 description 3
- 238000009792 diffusion process Methods 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 239000006260 foam Substances 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 239000003102 growth factor Substances 0.000 description 3
- 210000003494 hepatocyte Anatomy 0.000 description 3
- 230000002503 metabolic effect Effects 0.000 description 3
- 230000010412 perfusion Effects 0.000 description 3
- -1 polyethylene Polymers 0.000 description 3
- 238000012545 processing Methods 0.000 description 3
- 230000010076 replication Effects 0.000 description 3
- 239000002356 single layer Substances 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 238000012876 topography Methods 0.000 description 3
- 238000013459 approach Methods 0.000 description 2
- 230000017531 blood circulation Effects 0.000 description 2
- 230000036770 blood supply Effects 0.000 description 2
- 210000003321 cartilage cell Anatomy 0.000 description 2
- 238000012832 cell culture technique Methods 0.000 description 2
- 230000024245 cell differentiation Effects 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- 238000013461 design Methods 0.000 description 2
- 238000005530 etching Methods 0.000 description 2
- 239000007789 gas Substances 0.000 description 2
- 230000014509 gene expression Effects 0.000 description 2
- 230000002068 genetic effect Effects 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- 238000000465 moulding Methods 0.000 description 2
- 230000035790 physiological processes and functions Effects 0.000 description 2
- 210000003491 skin Anatomy 0.000 description 2
- 230000032258 transport Effects 0.000 description 2
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 1
- 208000007788 Acute Liver Failure Diseases 0.000 description 1
- 206010000804 Acute hepatic failure Diseases 0.000 description 1
- 239000000592 Artificial Cell Substances 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 102000003839 Human Proteins Human genes 0.000 description 1
- 108090000144 Human Proteins Proteins 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- 108010085895 Laminin Proteins 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 102000043299 Parathyroid hormone-related Human genes 0.000 description 1
- 101710123753 Parathyroid hormone-related protein Proteins 0.000 description 1
- 239000004952 Polyamide Substances 0.000 description 1
- 239000004698 Polyethylene Substances 0.000 description 1
- 239000004743 Polypropylene Substances 0.000 description 1
- 239000004793 Polystyrene Substances 0.000 description 1
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 1
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 1
- 238000001015 X-ray lithography Methods 0.000 description 1
- 231100000836 acute liver failure Toxicity 0.000 description 1
- 230000001464 adherent effect Effects 0.000 description 1
- 238000004026 adhesive bonding Methods 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 239000000560 biocompatible material Substances 0.000 description 1
- 238000004173 biogeochemical cycle Methods 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 210000000845 cartilage Anatomy 0.000 description 1
- 230000021164 cell adhesion Effects 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 230000008614 cellular interaction Effects 0.000 description 1
- 210000003850 cellular structure Anatomy 0.000 description 1
- 239000000919 ceramic Substances 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 239000002131 composite material Substances 0.000 description 1
- 210000002808 connective tissue Anatomy 0.000 description 1
- 229920001577 copolymer Polymers 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 210000004207 dermis Anatomy 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 238000000502 dialysis Methods 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 238000001312 dry etching Methods 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 238000009713 electroplating Methods 0.000 description 1
- 210000002889 endothelial cell Anatomy 0.000 description 1
- 230000001973 epigenetic effect Effects 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000012737 fresh medium Substances 0.000 description 1
- 239000012510 hollow fiber Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 210000005260 human cell Anatomy 0.000 description 1
- 239000000017 hydrogel Substances 0.000 description 1
- 239000007943 implant Substances 0.000 description 1
- 238000012606 in vitro cell culture Methods 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 238000001746 injection moulding Methods 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 210000004153 islets of langerhan Anatomy 0.000 description 1
- 210000002510 keratinocyte Anatomy 0.000 description 1
- 210000005229 liver cell Anatomy 0.000 description 1
- 229920002521 macromolecule Polymers 0.000 description 1
- 108010082117 matrigel Proteins 0.000 description 1
- 229940126601 medicinal product Drugs 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 210000000107 myocyte Anatomy 0.000 description 1
- 210000000885 nephron Anatomy 0.000 description 1
- 239000002547 new drug Substances 0.000 description 1
- 239000004745 nonwoven fabric Substances 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 238000001020 plasma etching Methods 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 229920003229 poly(methyl methacrylate) Polymers 0.000 description 1
- 229920002647 polyamide Polymers 0.000 description 1
- 239000004417 polycarbonate Substances 0.000 description 1
- 229920000515 polycarbonate Polymers 0.000 description 1
- 229920000573 polyethylene Polymers 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 239000004926 polymethyl methacrylate Substances 0.000 description 1
- 229920001155 polypropylene Polymers 0.000 description 1
- 229920002223 polystyrene Polymers 0.000 description 1
- 229920002635 polyurethane Polymers 0.000 description 1
- 239000004814 polyurethane Substances 0.000 description 1
- 229920000915 polyvinyl chloride Polymers 0.000 description 1
- 239000004800 polyvinyl chloride Substances 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 210000004927 skin cell Anatomy 0.000 description 1
- 230000007480 spreading Effects 0.000 description 1
- 238000003892 spreading Methods 0.000 description 1
- 238000013337 sub-cultivation Methods 0.000 description 1
- 231100000820 toxicity test Toxicity 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 230000004614 tumor growth Effects 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 210000000264 venule Anatomy 0.000 description 1
- 239000002699 waste material Substances 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12M—APPARATUS FOR ENZYMOLOGY OR MICROBIOLOGY; APPARATUS FOR CULTURING MICROORGANISMS FOR PRODUCING BIOMASS, FOR GROWING CELLS OR FOR OBTAINING FERMENTATION OR METABOLIC PRODUCTS, i.e. BIOREACTORS OR FERMENTERS
- C12M25/00—Means for supporting, enclosing or fixing the microorganisms, e.g. immunocoatings
- C12M25/10—Hollow fibers or tubes
Definitions
- the present invention relates to artificial cell carrier systems for three-dimensional cell growth and their use
- Growth is not only desirable for building up thicker layers, but also in order to maintain a functional cell structure such as an organ.
- Cellular structures show interactions between the cells or other tissues in addition to a high cell density Interactions are necessary epigenetic factors for cell proliferation and differentiation
- pore formation in these foams is important, since the cells settle in the pores or the nutrients are supplied via small pores in the material Dimensioning the pore n, however, can only be controlled inadequately. If the pores are too small, no cells can grow in there; if the pores are too large, undesired, two-dimensional cell growth takes place there.
- the nutrient supply that is crucial for the growth of the cells or the removal of metabolic products also depends on a defined one Pore size distribution from The difficult to control pore size distribution leads to insufficiently controllable cell growth So far, no functional tissue or organ clusters have been cultivated with these concepts.For uses that require a higher degree of differentiation and thicker cell layers, such as connective tissue or artificial organs, these techniques have failed.A reason for this is the unavoidable supply of thick cell layers with nutrient media and Oxygen, as is ensured in vivo by vascularization of the tissue.
- the cells can only be supplied with oxygen and nutrients via intercellular routes via a few cells or cell layers
- the individual cell layers are not in contact with one another, so there are two-dimensional layers stacked on top of one another and no three-dimensional structure
- JC Hager et al in J Natl Cancer Inst, 69, 6 (1982) describe a system of ordered bundles of hollow fibers for the growth of tumor cells. These fibers serve as a surface for cell adhesion and, via pores in the fibers, as a supply route for the provision of Nutrients and oxygen With them, three-dimensional cell growth can be achieved Orderly cell growth is not possible due to the difficult to control fiber spacing. Furthermore, the length, diameter and arrangement of the fibers determine the expansion and structure of the tissue to be grown
- WO 90/02796 and US 5 510 254 describe a further possibility of building approximately three-dimensional cell structures.
- mesh-like cell support structures optionally coated with growth-promoting substances, are used.
- the tissues can be arranged to superstructures, with a cellular connection between the individual layers depending on their distance and thus can only be influenced inadequately.
- Systems of this type are suitable for cell structures with a few layers; a complex, multi-layered three-dimensional cell structure cannot be grown with the aid of these tissues
- the object of the present invention was therefore to provide a cell carrier with which three-dimensional cell tissue can be grown in vitro and in vivo
- the present invention therefore relates to a cell carrier system made of porous material, the cell carrier system consisting of modularly shaped segments which are wholly or partly constructed from half-shells
- the porosity of the modularly shaped segments can be specifically adapted to the cell type used.
- the modularly shaped segments can have pores with an average diameter of 0.5 to 5 ⁇ m.
- the distribution of the pores is advantageously chosen such that between one and three pores are available per grown cell for the supply of the cells, ie the segments advantageously have pores with an average spacing of 1 to 10 ⁇ m.
- the segments of the cell carriers have a porous structure in whole or in part, with targeted cell growth preferably occurring only at the porous locations of the segments
- the non-porous areas of the segments can be used for fastening purposes or the like due to the reduced cell growth here
- the cell tissue grown on the cell carrier systems according to the invention is capable of proliferation in vitro and in vivo due to the excellent vascularization.
- the modular shape of the segments enables cell carrier systems of almost any shape and complexity to be built up.
- the optional connection between two or more segments enables the cultivation of practically any large, related cell and tissue cultures
- Cell carrier systems according to the present invention enable the construction of three-dimensional cell tissues in which all cells can be supplied with nutrient solution and oxygen via a porous and thus micro-structured surface
- the cells on the cell support systems according to the invention are supplied via a capillary system, which can be formed by combining the half-shells in each case with two modularly shaped systems.
- the segments can be combined in such a way that a closed hollow body, that is to say a capillary system, is formed from the two half-shells.
- the combination of two segments can be simplified by appropriate holding pins.
- the capillaries preferably have a diameter of 20-70 ⁇ m Such a system offers the possibility of distributing released growth factors throughout the cell culture and thereby enabling differentiation of the tissue. With the present invention it is possible to ensure a continuous outflow and inflow of nutrients, metabolites, oxygen and growth factors to the cell tissues
- the cell growth as well as the cell differentiation are significantly influenced by the surface topography of the cell carrier.
- the exchange of nutrients and the distribution of the cells on the surface is determined by the type and topography of the microstructure, ie in the present case by the porosity of the surface Diffusion of the metabolic activity of the tissue is limited
- the vascularization of the tissue also increases and thus reduces the necessary diffusion pathways
- the cell support systems consist of shaped segments which enable a modular structure of a composite system
- Suitable materials for the cell support systems according to the invention are, for example, polycarbonate, polymethyl methacrylate, polyurethane, polyamide, PVC, polyethylene, polypropylene, polystyrene or polysulfonate, and mixtures or copolymers thereof
- the fixing of two segments to form a capillary system can be done by gluing, microwave or radio frequency techniques. Of course, this must be done in a way that the pores of the material are not or only slightly affected
- the cell support systems can be they individual segments or preformed capillary systems, can be connected to each other. This can be achieved by using spacers, which are advantageously already fixed to them during the manufacture of the segments.
- the spacers also ensure a constant distance between them individual segment layers, so that cells can grow here too
- Modularly shaped segments preferably have spacers with a height of 20 to 200 ⁇ m. If the spacers are hollow and suitable for liquid transport, the nutrient solution can thus be guided through the entire system
- the modular design of the segments causes a mini-cry of the natural environment of the cells, so that proliferation, differentiation or the execution of the physiological functions of the cells takes place as long as the cells can be supplied with nutrient solution by the porous material.
- This supply usually takes place over 2 to 20 cell layers, the number of supplied cell layers strongly dependent on the metabolism of the cells Liver and kidney cells must be grown on cell support systems with small distances (20-40 ⁇ m), since they also require a high blood supply in the body
- the distance between the cell support systems fibroblasts and cartilage cells can be very large, up to 200 ⁇ m
- the individual segments can be produced using micro system technology.
- a suitable process is, for example, the LIGA process, a structuring process that is based on basic processes of X-ray lithography, electroplating and molding.
- the mold inserts produced by LIGA technology can then be used in injection molding, reactive resin molding or Any number of copies can be made from various plastics with high level of detail and at relatively low cost using the stamping process.
- the pores can be introduced into the material using suitable spinous processes on the mold inserts
- Fig. 2 shows an example of the structure of a cell carrier according to the invention from two segments.
- a segment consists of a central supply pipe, from which branches branch off vertically, at periodically repeating intervals.These branches form a capillary system.
- the surface of the segments is provided with small pores which depend on the the cell type used have a diameter of 0.5-5 ⁇ m.
- the pores have an average spacing of 1 to 10 ⁇ m, the distance between the branches (L1) can be between 20 and 200 ⁇ m, adapted to the cell type
- the nutrient medium is actively or passively pumped through a corresponding gradient through the central supply pipe.
- the distribution of the nutrient medium and the respiratory gases to Tissue is ensured by diffusion.
- the nutrient cycle is designed so that the medium can run off again via a drain and can be returned to the cycle or collected for further processing / disposal
- the individual segments have a modular structure so that they can be fitted together to form larger, three-dimensional objects.This creates an artificial capillary network that enables the cells to be vascularized almost naturally.
- the segments suitably have appropriate spacers as plug-in devices for a simple and precisely fitting connection between two Allow segments
- spacers In order to set the desired distances between the segments according to the invention, these are provided with spacers.
- the spacers expediently serve as a plug-in device for fixing two segments (AH in FIG. 3).
- the inflow and outflow are also designed so that the individual segments are in a liquid-carrying manner with one another Can be connected Hollow spacers can be used to connect the inflows and outflows of segments
- the segments can also be stacked offset from one another
- the desired cell types can be applied to the individual segments after the cell carrier has been built up.
- the system is placed in a roller bottle with a cell suspension of high density.In this bottle, the system remains at an average number of revolutions of the roller bottle until enough cells are on the Having fixed the surface This is typically completed after 3 to 8 hours. Then the system is transferred, preferably under sterile conditions, into a Petri dish and fresh medium is pumped through the cell supports through the supply connections of the segments. After a few days, the segment surfaces and thus a multilayer cell tissue between the channel walls
- the cell tissue can also be built up step by step.
- a level of the cell carrier according to the invention is incubated with cells. After a cell layer has grown on this, the lowest level, the system is gradually moved around a cell carrier layer extended to allow a cell layer to grow here as well
- the successive procedure has the advantage that different differentiation of a cell type can also be enforced by different spacing of the segments or the support layers. The different differentiation of a cell type is important e.g. in skin cells in practice have kept segment spacings of 3-6 cell layers
- the cell carriers according to the invention enable the cells to be well supplied with nutrients. This can be achieved by branching the segments.
- FIG. 4 a to e shows an exemplary embodiment of such a system based on a honeycomb structure. Food medium is pumped into this system through an inlet the medium run off and returned to the circuit or collected for further processing / disposal The surface of the segments is provided with small pores with a large size and distribution as already described. Combining the segments also creates an artificial capillary network in this embodiment variant
- the diameter of the individual honeycombs (“key width”) depends on the cell type used and can be between 70 and 180 ⁇ m.
- the next honeycomb-shaped cell carrier can be stacked over 90 degrees (FIG. 4 c) and stacked over the previous cell carrier become
- a three-dimensional cell culture can also be built up with honeycomb-shaped segments.
- appropriately designed plug connections between the honeycombs enable cell growth across layers (FIG. 4 e)
- the honeycomb-shaped cell carriers are constructed from two half shells or a half shell and a membrane which are firmly connected to one another
- FIG. 5 shows schematically the structure of such a cell carrier in a pyramidal design in the top (FIG. 5 a) and side view (FIGS. 5 b and c)
- Segments are periodically arranged in parallel rows (Fig. 5 c and d) between The rows remain at a distance, preferably from half the base area of a pyramid.
- the individual rows of segments can in turn be connected to one another by spacers which may be suitable for liquid transport.
- Nutrient medium is pumped through the elements via an inlet. The medium can run off via a drain, be returned to the circuit or be collected for further processing / disposal
- the surfaces of the pyramids are provided with small pores with size and distribution as described.
- the pyramids themselves are hollow, open at the base surface and thus also form a half-shell.
- the side view in FIG. 5 c shows the connection of two segments a closed cell support system
- a cell culture with pyramid-shaped cell support segments according to the invention can be constructed as follows: In a suitable cell culture system, some pyramid-shaped segments are applied to the base as a basic element. Above these structures, further segments can now be positioned. The combination of segments creates the cell supports (see side view Fig. 5 c ) The segments can be nested so that there is a distance between the surfaces of the pyramids in which the cells can grow
- the advantage of this structure is that the geometrical dimensions of the elements are independent of the selected cell type. Only the layer spacing and the pore diameter of the elements must be adapted to the cell type used in order to achieve the highest possible cell density or a small dead volume within the pyramids, ie the supply elements. a small height of the individual pyramid elements is recommended in comparison to their base area.
- the cell supports shown in FIG. 5 d have the following dimensions
- Width of the segments a3 150 - 300 ⁇ m Length of the segments a5 integer multiples of a3 Distance of the cell carriers a4 50 - 300 ⁇ m
- these can also be formed by combining a half-shell of a modularly shaped segment with a semi-permeable membrane while building a capillary system.A permeable membrane is stretched on the back of a segment.
- the protruding membrane parts can be removed using suitable etching processes Technology has the advantage that two segments do not have to be assembled precisely.
- Semipermeable membranes such as Gorotex, Simpatex or ceramic membranes are suitable for this purpose. Plasma etching has proven to be a preferred etching process.
- the protruding membrane portions are removed in a plasma reactor with plasma gases such as F 2 , Cl 2 , CF 3 7F, CC1 3 + / C1 and O 2 etches
- plasma gases such as F 2 , Cl 2 , CF 3 7F, CC1 3 + / C1 and O 2 etches
- This embodiment of the present invention also ultimately creates closed cavities or capillaries.
- the pore size and distribution of the membranes correspond to those of the segments with an average distance of 1 to 10 ⁇ m and an average diameter of 0.5 to 5 ⁇ m
- Another object of the present invention is the use of the three-dimensional cell support systems for bioreactors and for the cultivation of eukaryotic or organic stem cells
- Important stem cells are heptocytes, kidney cells, endothelial cells, epithelial cells or myocytes
- human proteins By using cell carriers according to the invention which are optimized for human cell types, human proteins can thus also be synthesized. This means that the structure and in particular the folding of the synthetic proteins corresponds to the natural proteins of the human body
- the proteins or other substances produced by the cells can be continuously removed via the nutrient supply cycle. In the case of non-adherent systems, this is only possible by filtration or by centrifuging the suspensions. For example, the development of cell cultures as an implant up to artificial hybrid organs
- cell carrier systems according to the invention has the advantage that the hepatocytes are not present in a suspension but can grow organotypically. This ensures that the heptatocytes achieve a degree of differentiation which is also present in vitro
- the hepatocytes can be adequately supplied.
- the individual segments are switched in such a way that there is only one inlet and one outlet Protection from infection is closed by an external encapsulation.
- the blood circulation of a patient can then be closed via the inflow and outflow in the outside.
- the cells then take over the function of the liver.
- other artificial organs such as a Kidney to be built up
- the replication of artificial tissue and tissue replacement on cell supports according to the invention offers decisive advantages in the toxicity test. Encapsulation is not necessary for the replication of the skin.In imitation of the anatomical model, the blood supply to the dermis must decrease more and more when artificial skin is being grown Increasing distances between the segments in the cell culture can be achieved. Because the artificial vascularization due to this construction lies in precisely defined cell layers, this can also be used for penetration tests. For such tests, the elements in the cell culture must be supplied in layers, so that only nutrient medium can be removed for analysis in the desired cell layer.
- the use of cell carriers according to the invention has advantages in particular in the creation of disease models.
- the cells that carry the characteristic features of the disease at the cellular level are brought into a cell culture and are kept in a 3D culture by segments. This technique keeps the cells longer in the "pathological" physiological state and does not redifferentiate again so quickly.
- the use of such models is primarily in the pharmaceutical industry, which can test new drugs on such models. Furthermore, such models can make a decisive contribution to understanding some diseases
Landscapes
- Health & Medical Sciences (AREA)
- Wood Science & Technology (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical & Material Sciences (AREA)
- Zoology (AREA)
- Biomedical Technology (AREA)
- Sustainable Development (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Immunology (AREA)
- Apparatus Associated With Microorganisms And Enzymes (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Immobilizing And Processing Of Enzymes And Microorganisms (AREA)
Abstract
Systèmes de support cellulaire constitués par des demi-coques en matière poreuse. Par combinaison entre elles ou avec une membrane semi-perméable, lesdites demi-coques peuvent former un système capillaire. Lesdits systèmes peuvent être utilisés pour la culture de cellules souches eucaryotes ou organiques ou pour des bioréacteurs.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE19919242 | 1999-04-28 | ||
| DE1999119242 DE19919242A1 (de) | 1999-04-28 | 1999-04-28 | Modulare Zellträgersysteme für dreidimensionales Zellwachstum |
| PCT/EP2000/001913 WO2000066712A2 (fr) | 1999-04-28 | 2000-03-04 | Systemes modulaires de support cellulaire pour la croissance cellulaire en trois dimensions |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| EP1171572A2 true EP1171572A2 (fr) | 2002-01-16 |
Family
ID=7906114
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EP00912550A Withdrawn EP1171572A2 (fr) | 1999-04-28 | 2000-03-04 | Systemes modulaires de support cellulaire pour la croissance cellulaire en trois dimensions |
Country Status (6)
| Country | Link |
|---|---|
| EP (1) | EP1171572A2 (fr) |
| JP (1) | JP2002542817A (fr) |
| CA (1) | CA2372219A1 (fr) |
| DE (1) | DE19919242A1 (fr) |
| WO (1) | WO2000066712A2 (fr) |
| ZA (1) | ZA200109700B (fr) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8846393B2 (en) | 2005-11-29 | 2014-09-30 | Gamida-Cell Ltd. | Methods of improving stem cell homing and engraftment |
| US20080206735A1 (en) * | 2007-02-28 | 2008-08-28 | Cinvention Ag | High surface cultivation system with surface increasing substrate |
| DE102008050424B4 (de) | 2008-10-08 | 2010-11-25 | Universität Leipzig | Verfahren und Vorrichtung zur homogenen Verteilung einer zellulären Suspension in porösem Trägermaterial für die Herstellung von vitalem biologischem Ersatzgewebe |
| WO2011073261A2 (fr) * | 2009-12-16 | 2011-06-23 | Vivabiocell Spa | Dispositif de culture en continu |
| JP6348848B2 (ja) | 2012-02-13 | 2018-06-27 | ガミダ セル リミテッド | 間葉系幹細胞の増殖 |
| US9175266B2 (en) | 2012-07-23 | 2015-11-03 | Gamida Cell Ltd. | Enhancement of natural killer (NK) cell proliferation and activity |
| US9567569B2 (en) | 2012-07-23 | 2017-02-14 | Gamida Cell Ltd. | Methods of culturing and expanding mesenchymal stem cells |
| US20190136218A1 (en) | 2016-05-05 | 2019-05-09 | Danisco Us Inc | Protease variants and uses thereof |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5510254A (en) * | 1986-04-18 | 1996-04-23 | Advanced Tissue Sciences, Inc. | Three dimensional cell and tissue culture system |
| US5605835A (en) * | 1988-05-23 | 1997-02-25 | Regents Of The University Of Minnesota | Bioreactor device with application as a bioartificial liver |
| DE4206585C2 (de) * | 1992-03-03 | 1994-11-24 | Augustinus Dr Med Bader | Vorrichtung zur Massenkultur von Zellen |
| JP4112616B2 (ja) * | 1995-10-06 | 2008-07-02 | シード・キャピタル・インベストメンツ−2(エスシーアイ−2)・ビー・ブイ | 細胞培養、特に肝細胞の培養に使用するための固相支持体、前記固相支持体を含む生物的リアクター、およびバイオ人工肝臓システムにおけるその使用 |
-
1999
- 1999-04-28 DE DE1999119242 patent/DE19919242A1/de not_active Withdrawn
-
2000
- 2000-03-04 CA CA002372219A patent/CA2372219A1/fr not_active Abandoned
- 2000-03-04 JP JP2000615737A patent/JP2002542817A/ja active Pending
- 2000-03-04 WO PCT/EP2000/001913 patent/WO2000066712A2/fr not_active Ceased
- 2000-03-04 EP EP00912550A patent/EP1171572A2/fr not_active Withdrawn
-
2001
- 2001-11-26 ZA ZA200109700A patent/ZA200109700B/en unknown
Non-Patent Citations (1)
| Title |
|---|
| See references of WO0066712A3 * |
Also Published As
| Publication number | Publication date |
|---|---|
| JP2002542817A (ja) | 2002-12-17 |
| DE19919242A1 (de) | 2000-11-02 |
| WO2000066712A2 (fr) | 2000-11-09 |
| WO2000066712A3 (fr) | 2001-04-19 |
| ZA200109700B (en) | 2002-06-26 |
| CA2372219A1 (fr) | 2000-11-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE69633189T2 (de) | Fester Träger zur Verwendung in der Zellkultivierung, insbesondere für die Kultivierung von Leberzellen, Bioreaktor, welcher den festen Träger enthält, und die Verwendung davon in einem biologisch-künstlichen Lebersystem | |
| EP0605527B1 (fr) | Substrat pour cultures de cellules | |
| EP0983341B1 (fr) | Dispositif pour la culture et/ou le traitement de cellules | |
| EP0629237B1 (fr) | Dispositif pour le traitement de cultures cellulaires | |
| DE60017900T2 (de) | Herstellung von dreidimensionalem vaskularisierten gewebe mittels der verwendung von zweidimensionalen mikrohergestellten formen | |
| DE69221837T2 (de) | In vivo sekretion von aktiven faktoren durch ko-kultivierte zellimplantate | |
| DE60213432T2 (de) | Verfahren und anlyse zur züchtung von organischen gewebekulturen | |
| Zhang et al. | Microfluidic bioprinting for engineering vascularized tissues and organoids | |
| AT506826B1 (de) | Bioreaktor und verfahren zum kultivieren von zellen und geweben | |
| DE10326750B4 (de) | Verfahren zur Herstellung einer Zellpräparation und derart hergestellte Zellpräparationen | |
| US12084642B2 (en) | Cell culture device | |
| DE102006031871B4 (de) | 3-D Petri-Schale zur Züchtung und Untersuchung von Zellen | |
| WO2003020871A2 (fr) | Procede et dispositif de culture cellulaire in vitro | |
| US7695958B2 (en) | Cell-filled hollow fiber membranes having modified cross-section | |
| EP4146394A1 (fr) | Dispositif microfluidique | |
| EP1171572A2 (fr) | Systemes modulaires de support cellulaire pour la croissance cellulaire en trois dimensions | |
| DE10326744B4 (de) | Modul zur Züchtung und zur Nutzung der Stoffwechselleistung und/oder zum Erhalt von Mikroorganismen, Verfahren zu dessen Herstellung und Verwendung | |
| DE10326747B4 (de) | Perfusionseinheit und Perfusionsstation zur Hautwundbehandlung sowie dessen Verwendung | |
| WO2020120466A1 (fr) | Modèle de choroïde microphysiologique | |
| DE19919241A1 (de) | 3D Zellträgersystem für Zell-, Gewebe- und Organkulturen | |
| DE10326749B4 (de) | Hybrides Kreislaufsystem | |
| EP1981965B1 (fr) | Procédé de culture de cellules biologiques | |
| Morelli et al. | Membrane reactors in bioartificial organs | |
| EP1177829A2 (fr) | Membranes compatibles avec le sang et le tissu à base de copolymères d'acrylonitrile/N-vinylpyrrolidone et leur utilisation dans le domaine de la médecine | |
| EP4308680A1 (fr) | Chambre de culture cellulaire et procédé de mise en culture de cellules et de production in vitro de couches cellulaires et de modèles d'organes |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
| 17P | Request for examination filed |
Effective date: 20011017 |
|
| AK | Designated contracting states |
Kind code of ref document: A2 Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE |
|
| 17Q | First examination report despatched |
Effective date: 20021023 |
|
| STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN |
|
| 18D | Application deemed to be withdrawn |
Effective date: 20030304 |